Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
WDB coco Co., Ltd. (7079.T)
Tokyo, JP
WDB coco Co., Ltd. offers specialized contractual services to pharmaceutical companies throughout Japan. The firm plays a crucial role in advancing pharmaceuticals and medical devices, with a particular focus on safety information management, support for safety data systems, clinical research assistance, and post-market safety operations. Its offerings also encompass translation and quality control document preparation, additional clinical study support, and personnel dispatch. Furthermore, WDB coco provides comprehensive post-marketing surveillance (PMS) solutions, which include securing agreements with healthcare facilities, explaining survey protocols, collecting survey forms, conducting detailed monitoring (like re-surveys), managing a central case registration center, handling data, and performing statistical analyses. Established in 1984, the company's headquarters are located in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.70% | -1.65% | -3.33% | -5.40% | -1.43% | -6.17% | -11.68% | -53.93% | -22.98% | -27.67% | -27.67% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-9.6% Q1'26: -11.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-25.6% Q1'26: -12.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+14.7% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+19.9% ★ Q1'26: +25.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+61.2% ★ Q1'26: +79.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.08× ★ Q1'26: 0.07× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
2.29B
est: 2.28B (+0.2%)
|
2.57B
est: 2.60B (-1.1%)
|
3.62B
est: 3.61B (+0.2%)
|
4.07B
est: 4.00B (+1.8%)
|
4.60B
est: 4.60B (-0.1%)
|
5.33B
est: 5.10B (+4.4%)
|
5.60B
5.60B – 5.60B
+9.8% YoY
|
6.10B
6.10B – 6.10B
+8.9% YoY
|
| EBITDA |
482.85M
est: 590.91M (-18.3%)
|
536.06M
est: 673.84M (-20.4%)
|
981.71M
est: 935.08M (+5.0%)
|
1.12B
est: 1.04B (+7.8%)
|
1.31B
est: 1.41B (-7.3%)
|
1.36B
est: 1.32B (+3.0%)
|
1.45B
1.45B – 1.45B
+9.8% YoY
|
1.58B
1.58B – 1.58B
+8.9% YoY
|
| EBIT |
473.48M
est: 574.96M (-17.7%)
|
524.70M
est: 655.66M (-20.0%)
|
963.36M
est: 909.85M (+5.9%)
|
1.09B
est: 1.01B (+7.6%)
|
1.27B
est: 1.33B (-4.4%)
|
1.31B
est: 1.28B (+2.1%)
|
1.40B
1.40B – 1.40B
+9.8% YoY
|
1.53B
1.53B – 1.53B
+8.9% YoY
|
| Net Income |
306.56M
est: 284.25M (+7.8%)
|
373.18M
est: 421.09M (-11.4%)
|
647.70M
est: 641.14M (+1.0%)
|
743.63M
est: 664.46M (+11.9%)
|
857.83M
est: 809.96M (+5.9%)
|
912.90M
est: 899.90M (+1.4%)
|
999.94M
999.94M – 999.94M
+11.1% YoY
|
1.10B
1.10B – 1.10B
+10.0% YoY
|
| SGA |
396.29M
est: 313.50M (+26.4%)
|
376.17M
est: 357.50M (+5.2%)
|
472.34M
est: 496.09M (-4.8%)
|
498.13M
est: 549.99M (-9.4%)
|
660.10M
est: 630.99M (+4.6%)
|
761.06M
est: 709.78M (+7.2%)
|
779.36M
779.36M – 779.36M
+9.8% YoY
|
848.95M
848.95M – 848.95M
+8.9% YoY
|
| EPS |
134.16
est: 118.20 (+13.5%)
|
163.11
est: 175.10 (-6.8%)
|
273.94
est: 266.60 (+2.8%)
|
311.24
est: 276.30 (+12.6%)
|
356.90
est: 336.80 (+6.0%)
|
379.61
est: 374.20 (+1.4%)
|
415.80
415.80 – 415.80
+11.1% YoY
|
457.40
457.40 – 457.40
+10.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Atsushi Imamura | Executive Officer, Head of Clinical Research Division & Director | — | — |
| Haruhiko Taniguchi | President, Chief Executive Officer & Representative Chairman | — | male |
| Hatsune Hiramitsu | GM of Contract Business Department & Director | — | female |
| Kazutaka Saito | Executive Officer, Head of Administration Division & Director | — | — |
| Soko Fujihara | GM of Productivity Monitoring Department & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7079.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
